🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jason L. Weirather

Biogen (United States)

ORCID: 0000-0003-0556-0616

Also affiliated with Dana-Farber Cancer Institute, Medidata (United States)

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
0.962Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3251
Top 32%
0.613DataRank
Top 32%15 citations

Jingxin Fu, Carrie Cibulskis, Aashna Jhaveri, Curtis Gumbs, Biswajit Das +41 more

Papers

Driven by 18 papers — median percentile 25. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6
N/A
4.8DataRank · unranked
234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood(2020)10.1182/blood.2020006464
N/A
1.9DataRank · unranked
59 citations

Jason L. Weirather, Margaretha G.M. Roemer, Mikel Lipschitz, Alyssa Kelley, Pei-Hsuan Chen +26 more

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2250
N/A
0.979DataRank · unranked
35 citations

Michael J. Nathenson, Emanuele Mazzola, Jia‐Ren Lin, Joanna Bagińska, Allison Nau +11 more

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0812
N/A
0.848DataRank · unranked
284 citations

Wubing Zhang, Xiaoqing Wang, Peng Jiang, Nicole Traugh, Ziyi Li +28 more

Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments

Immunity(2022)10.1016/j.immuni.2022.03.020
N/A
0.681DataRank · unranked
93 citations

Chi Ngai Chan, Xavier Rovira‐Clavé, Han Chen, Yunhao Bai, Bokai Zhu +27 more

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3251
Top 32%
0.613DataRank
Top 32%15 citations

Jingxin Fu, Carrie Cibulskis, Aashna Jhaveri, Curtis Gumbs, Biswajit Das +41 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3
N/A
0.604DataRank · unranked
55 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging

Blood Advances(2023)10.1182/bloodadvances.2023009813
N/A
0.538DataRank · unranked
35 citations

Jason L. Weirather, Sizun Jiang, Katrina Kao, Yari Sigal, Anita Giobbie‐Hurder +3 more

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade

Cancer Immunology Research(2023)10.1158/2326-6066.cir-23-0171
N/A
0.500DataRank · unranked
27 citations

Dinesh Thapa, Anita Giobbie‐Hurder, Jason L. Weirather, Marco Campisi, Pieter J. Schol +7 more

Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression

Cancer Immunology Research(2022)10.1158/2326-6066.cir-22-0227
N/A
0.470DataRank · unranked
22 citations

Shengqing Gu, Nofal Ouardaoui, Carly Tymm, Lin Yang, Cheryl J. Wong +9 more

A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma

Nature Cancer(2025)10.1038/s43018-025-01053-7
N/A
0.351DataRank · unranked
9 citations

Thinh T. Nguyen, Atharva Bhagwat, Akhil Kumar, Bruno Giotti, Benjamin Kepecs +29 more

A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.28.546977
Top 50%
0.349DataRank
Top 50%5 citations

Benjamin Kepecs, Navin R. Mahadevan, Jason L. Weirather, Naomi R. Besson, Bruno Giotti +19 more

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab

OncoImmunology(2024)10.1080/2162402x.2024.2432723
N/A
0.292DataRank · unranked
6 citations

Giuseppe Tarantino, Mariano Severgnini, Joanna Bagińska, Anita Giobbie‐Hurder, Jason L. Weirather +14 more

700 Increasing MHC-I expression to potentiate immune checkpoint blockade therapy

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.700
N/A
0.104DataRank · unranked
1 citations

Wubing Zhang, Xiaoqing Wang, Peng Jiang, Nicole Traugh, Ziyi Li +28 more

Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2616
N/A
0DataRank · unranked
0 citations

Nilofer S. Azad, Jennifer Lee, Jacob P. K. Gross, Michael J. Overman, Katrina Kao +14 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

MAPS: pathologist-level cell type annotation from tissue images through machine learning

Nature Communications(2024)10.1038/s41467-023-44188-w
N/A
0DataRank · unranked
50 citations

Yunhao Bai, Huaying Qiu, Shulin Mao, Jason Yeung, Yao Yu Yeo +10 more